Combining radiation plus immunotherapy to improve systemic immune response

被引:48
作者
Cushman, Taylor R. [1 ]
Gomez, Daniel [1 ]
Kumar, Rachit [1 ,2 ]
Likacheva, Anna [1 ,2 ]
Chang, Joe Y. [1 ]
Cadena, Alex P. [1 ]
Paris, Sebastien [3 ]
Welsh, James W. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Banner MD Anderson Canc Ctr, Dept Radiat Oncol, Phoenix, AZ USA
[3] Nanobiotix, Dept Biol Discovery, Paris, France
关键词
Immunotherapy; radiation therapy (RT); radiotherapy; abscopal; lung cancer; CELL LUNG-CANCER; STEREOTACTIC ABLATIVE RADIOTHERAPY; 1ST-LINE THERAPY; TUMOR-STROMA; PHASE-II; T-CELLS; TRIAL; RESISTANCE; MELANOMA; PD-1;
D O I
10.21037/jtd.2018.01.130
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Over the past decade, the fields of oncology have made great strides in therapies. The development of new therapeutics and increased understanding of the role of the immune system in the development and treatment of cancer has led to increased collaboration between oncologic fields. Recent technologic advancements in radiation therapy (RT), including stereotactic beam radiation therapy (SBRT), have improved local control and offer an alternative to surgery for the control of oligometastatic disease. Immunotherapy has proven a promising therapeutic in the treatment of metastatic disease but treatment resistance remains a significant obstacle in the majority of patients. Together, radiation and immunotherapy offer potential to eliminate metastatic disease, reduce time to recurrence and improve overall survival. Major obstacles to these positive outcomes include high tumor burden, intratumoral heterogeneity, and the negative effects of tumor stroma, to name a few. Multimodality treatments are under heavy investigation. Promising data from clinical trials is emerging to highlight the value of RT in combination with immunotherapy. However, the mechanisms behind their synergistic effects remain to be fully elucidated. This review aims to highlight the existing literature and offers hypotheses to explain mechanisms behind the synergy of RT and immunotherapy.
引用
收藏
页码:S468 / S479
页数:12
相关论文
共 49 条
[1]   Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].
Ahmadzadeh, Mojgan ;
Johnson, Laura A. ;
Heemskerk, Bianca ;
Wunderlich, John R. ;
Dudley, Mark E. ;
White, Donald E. ;
Rosenberg, Steven A. .
BLOOD, 2009, 114 (08) :1537-1544
[2]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[3]   An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer [J].
Ashworth, Allison B. ;
Senan, Suresh ;
Palma, David A. ;
Riquet, Marc ;
Ahn, Yong Chan ;
Ricardi, Umberto ;
Congedo, Maria T. ;
Gomez, Daniel R. ;
Wright, Gavin M. ;
Melloni, Giulio ;
Milano, Michael T. ;
Sole, Claudio V. ;
De Pas, Tommaso M. ;
Carter, Dennis L. ;
Warner, Andrew J. ;
Rodrigues, George B. .
CLINICAL LUNG CANCER, 2014, 15 (05) :346-355
[4]   Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients [J].
Baitsch, Lukas ;
Baumgaertner, Petra ;
Devevre, Estelle ;
Raghav, Sunil K. ;
Legat, Amandine ;
Barba, Leticia ;
Wieckowski, Sebastien ;
Bouzourene, Hanifa ;
Deplancke, Bart ;
Romero, Pedro ;
Rufer, Nathalie ;
Speiser, Daniel E. .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (06) :2350-2360
[5]   The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence [J].
Barker, Holly E. ;
Paget, James T. E. ;
Khan, Aadil A. ;
Harrington, Kevin J. .
NATURE REVIEWS CANCER, 2015, 15 (07) :409-425
[6]   Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? [J].
Bernstein, Michael B. ;
Krishnan, Sunil ;
Hodge, James W. ;
Chang, Joe Y. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :516-524
[7]   Putting tumours in context [J].
Bissell, MJ ;
Radisky, D .
NATURE REVIEWS CANCER, 2001, 1 (01) :46-54
[8]   Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection [J].
Blackburn, Shawn D. ;
Shin, Haina ;
Haining, W. Nicholas ;
Zou, Tao ;
Workman, Creg J. ;
Polley, Antonio ;
Betts, Michael R. ;
Freeman, Gordon J. ;
Vignali, Dario A. A. ;
Wherry, E. John .
NATURE IMMUNOLOGY, 2009, 10 (01) :29-37
[9]   First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas [J].
Bonvalot, Sylvie ;
Le Pechoux, Cecile ;
De Baere, Thierry ;
Kantor, Guy ;
Buy, Xavier ;
Stoeckle, Eberhard ;
Terrier, Philippe ;
Sargos, Paul ;
Coindre, Jean Michel ;
Lassau, Nathalie ;
Sarkouh, Rafik Ait ;
Dimitriu, Mikaela ;
Borghi, Elsa ;
Levy, Laurent ;
Deutsch, Eric ;
Soria, Jean-Charles .
CLINICAL CANCER RESEARCH, 2017, 23 (04) :908-917
[10]   Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer [J].
Brooks, Eric D. ;
Sun, Bing ;
Zhao, Lina ;
Komaki, Ritsuko ;
Liao, Zhonxing ;
Jeter, Melenda ;
Welsh, James W. ;
O'Reilly, Michael S. ;
Gomez, Daniel R. ;
Hahn, Stephen M. ;
Heymach, John V. ;
Rice, David C. ;
Chang, Joe Y. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (04) :900-907